Recent Updates
Recently added Catalysts
ARGX Positive Sentiment Score: 75/100

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

Monday, July 27, 2026 1 min read
Key Takeaway: argenx has announced its acquisition of Forte Biosciences for $77 per share, totaling approximately $2.2 billion. This strategic move aims to enhance argenx's immunology portfolio by adding FB102, a first-in-class anti-CD122 antibody. The acquisition reflects argenx's commitment to expanding its innovative treatment options in immunology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Acquisition enhances argenx's immunology pipeline.
  • FB102 is a first-in-class anti-CD122 antibody.
  • The deal signifies strong growth potential for argenx.

Full Press Release Details

AMSTERDAM & DALLAS--(BUSINESS WIRE)--argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc.  (Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-

Frequently Asked Questions

What is the acquisition price for Forte Biosciences?

The acquisition price for Forte Biosciences is $77 per share.

What is FB102?

FB102 is Forte Biosciences' lead program, a first-in-class anti-CD122 antibody.

What is the total equity value of the acquisition?

The total equity value of the acquisition is approximately $2.2 billion.

How does this acquisition benefit argenx?

The acquisition enhances argenx's portfolio of differentiated immunology medicines.

Tags: ARGX Viatris Investor Conferences Healthcare argenx Forte Biosciences FB102 immunology acquisition
Last updated: Jul 27, 2026

Biotech snapshot

Lead asset
efgartigimod PH20Phase 3
Primary Immune Thrombocytopenia →

Catalyst track record

+36%
best trade around ARGX's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for ARGX.

See every catalyst's timing & PoA →